Investigators seeking verified short bioregulatory peptides for extracellular matrix and chondrocyte research rely on high-purity analytical compounds. Cartalax (Ala-Glu-Asp) supplied by PX1 Research is manufactured under strict domestic quality controls for in vitro and preclinical experimental applications. Each lot undergoes comprehensive third-party testing to guarantee chemical identity, purity, and freedom from bacterial endotoxins.
Investigators seeking verified short bioregulatory peptides for extracellular matrix and chondrocyte research rely on high-purity analytical compounds. Cartalax (Ala-Glu-Asp) supplied by PX1 Research is manufactured under strict domestic quality controls for in vitro and preclinical experimental applications. Each lot undergoes comprehensive third-party testing to guarantee chemical identity, purity, and freedom from bacterial endotoxins.
Cartalax for sale through accredited chemical suppliers like PX1 Research is provided strictly as a lyophilized, research-grade tripeptide (Ala-Glu-Asp) intended for in vitro cellular assays and non-human preclinical models. Laboratory procurement requires verified sequence identity, HPLC purity exceeding 98%, and lot-specific certificates of analysis (COA) to guarantee experimental repeatability across connective tissue studies.
When acquiring research peptides for institutional or private laboratory investigations, establishing analytical consistency across experimental replicates is paramount. Impurities, peptide truncations, or residual manufacturing solvents can introduce uncontrolled variables into sensitive cell culture models or enzymatic assays. Principal investigators can review our full inventory of verified research peptides to ensure consistent quality standards across all experimental designs.
PX1 Research maintains rigorous manufacturing oversight for every batch of Cartalax. By utilizing domestic USA synthesis facilities that operate under GMP compliance, PX1 eliminates the supply chain uncertainties and quality control variations frequently associated with unverified foreign suppliers.
Cartalax is a synthetic short bioregulatory peptide comprised of three amino acids in the sequence L-Alanyl-L-Glutamyl-L-Aspartic Acid (Ala-Glu-Asp, molecular formula C12H19N3O8). It belongs to a specific class of low-molecular-weight peptide bioregulators developed to study targeted gene expression and cellular differentiation in specific tissue lineages.
With a molecular weight of approximately 333.29 g/mol, Cartalax represents a minimalist peptide structure designed for efficient nuclear or cellular interaction in laboratory models. Unlike large protein constructs or complex extracellular proteins, short tripeptides exhibit high chemical stability and predictable solubility in standard physiological buffers.
In structural biology and biochemical assays, the specific arrangement of Alanine, Glutamic Acid, and Aspartate creates a polar, acidic tripeptide motif. This configuration allows researchers to investigate electrostatic interactions with chromatin components, histone proteins, and specific double-stranded DNA promoter sequences under cell-free or cell-culture conditions. Further details on tripeptide dynamics can be explored through our dedicated research library.
Preclinical investigations into Cartalax focus primarily on its capacity to modulate chondrocyte gene expression and extracellular matrix (ECM) homeostasis. In vitro assays using primary articular chondrocytes and cartilage explants demonstrate that exposure to short alanine-glutamate-aspartate sequences influences the transcription of key structural macromolecules.
In vitro data indicate that Cartalax upregulates the gene expression of Type II Collagen (COL2A1) and Aggrecan (ACAN), two vital components of the articular cartilage matrix. Concurrently, preclinical models suggest that the tripeptide may suppress the transcriptional activation of matrix metalloproteinases (such as MMP-3 and MMP-13) and inflammatory cytokines like IL-1β and TNF-α, which are typically associated with ECM degradation.
Emerging research into the Cartalax mechanism of action highlights potential epigenetic mechanisms. Evidence suggests that short bioregulatory tripeptides penetrate the cell nucleus and bind selectively to specific promoter regions within DNA, inducing chromatin remodeling and regulating protein synthesis without altering the underlying genomic sequence.
To contextualize Cartalax within connective tissue and musculoskeletal research, scientists frequently compare its performance against other synthetic peptides investigated for tissue repair and cellular homeostasis. The table below outlines key differences observed in preclinical models among leading candidate peptides.
While Cartalax functions primarily as a nuclear gene regulator targeting chondrocyte differentiation and collagen expression, compounds like BPC-157 operate through distinct angiogenic and growth factor signaling pathways to support tendon and ligament models. Meanwhile, tripeptides such as KPV are routinely evaluated for anti-inflammatory cytokine modulation in epithelial and systemic tissue studies.
Researchers exploring broader cellular protection and longevity models often study Cartalax alongside other short sequence bioregulators such as Epithalon or Pinealon. Reviewing the overarching literature on bioregulatory peptides provides additional context regarding how sequence variation alters tissue specificity and nuclear binding affinity in experimental frameworks.
High-purity research materials are essential for producing reproducible, publishable data. PX1 Research enforces a multi-tier analytical testing protocol for every batch of Cartalax for sale, verifying chemical identity, sequence accuracy, and purity prior to distribution.
Primary purity analysis is performed via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). RP-HPLC separates the target tripeptide from synthesis side-products, truncated sequences, and residual protecting groups. PX1 Research guarantees a minimum HPLC purity of 98.0% for all Cartalax lots, ensuring minimal background noise in sensitive bioassays.
Identity verification is established using Electrospray Ionization Mass Spectrometry (ESI-MS), confirming the precise molecular weight of 333.29 Da. In addition, every lot undergoes Chromogenic Reagent LAL (Limulus Amebocyte Lysate) testing to ensure bacterial endotoxin levels remain strictly below <0.01 EU/mg, preventing endotoxin-induced artifactual inflammatory responses in cell culture models.
Cartalax is supplied as a lyophilized (freeze-dried) sterile powder in sealed glass serum vials to maintain long-term stability. Proper reconstitution protocols are critical to preserving peptide integrity and ensuring accurate molar concentration in laboratory reagents.
For most cell culture and biochemical assays, lyophilized Cartalax should be reconstituted using sterile, cell-culture-grade water, phosphate-buffered saline (PBS, pH 7.4), or sterile 0.9% sodium chloride solution. The polar nature of the Ala-Glu-Asp tripeptide allows rapid dissolution without aggressive mechanical agitation.
When reconstituting, gently direct the solvent down the inner glass wall of the vial rather than splashing directly onto the lyophilized cake. Allow the vial to sit at room temperature for 1–2 minutes, then swirl gently until complete dissolution is achieved. Avoid intense vortexing or vigorous shaking, which can cause protein shearing or foam formation that complicates accurate volumetric pipetting.
Lyophilized Cartalax exhibits excellent stability when stored under appropriate environmental conditions. Unopened vials stored in a desiccated freezer environment at -20°C (or -80°C for ultra-long-term archiving) remain stable for up to 24 months from the date of synthesis.
Once reconstituted into liquid solution, Cartalax should be aliquoted into single-use microcentrifuge tubes to prevent degradation caused by repeated freeze-thaw cycles. Reconstituted aqueous solutions stored at 2°C to 8°C should be utilized within 7 to 14 days, depending on the buffer system and sterility controls employed.
For extended experimental runs utilizing liquid media, reconstituted aliquots should be stored at -20°C and thawed immediately prior to introduction into culture systems. Exposure to direct ultraviolet light, elevated ambient temperatures, and repeated thermal cycling must be minimized to preserve optimal peptide function.
PX1 Research is committed to supplying the scientific community with fully traceable, American-manufactured research chemicals. All peptide synthesis, freeze-drying, and vial packaging take place in domestic, GMP-compliant facilities adhering to ISO 9001 and ISO 17025 quality management frameworks.
Every vial of Cartalax sold features a unique lot number linked directly to its corresponding Certificate of Analysis. Principal investigators can download public COA documentation directly from our portal to inspect raw HPLC chromatograms, mass spectra, and endotoxin assay reports prior to initiating experimental procedures.
To support high-throughput laboratory operations and multi-phase research studies, PX1 Research offers flexible ordering options, including direct online procurement and dedicated wholesale accounts for institutional purchasing departments. All orders placed Monday through Friday before our daily cutoff dispatch same-day from our fulfillment centers in California and Arizona.
What is the intended use when purchasing Cartalax for sale?
Cartalax for sale through PX1 Research is strictly intended for in vitro cellular research, molecular biology assays, and preclinical non-human laboratory models. It is not licensed, approved, or formulated for human consumption, therapeutic, or diagnostic applications.
How is the purity of PX1 Research Cartalax verified?
Every lot of Cartalax undergoes independent third-party testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity ≥98%, Mass Spectrometry (ESI-MS) to verify molecular weight, and LAL assays to confirm endotoxin levels <0.01 EU/mg.
What is the amino acid sequence and molecular weight of Cartalax?
Cartalax is a synthetic tripeptide with the amino acid sequence L-Alanyl-L-Glutamyl-L-Aspartic Acid (Ala-Glu-Asp). It has a molecular formula of C12H19N3O8 and a monoisotopic molecular weight of approximately 333.29 g/mol.
What solvent is recommended for reconstituting Cartalax in laboratory assays?
Cartalax dissolves readily in sterile cell-culture-grade water, phosphate-buffered saline (PBS, pH 7.4), or sterile 0.9% sodium chloride. Solution selection depends on the specific buffer requirements of your in vitro or enzymatic assay.
How does Cartalax differ from BPC-157 in preclinical models?
Cartalax is a 3-amino-acid bioregulatory tripeptide focused on epigenetic gene expression, collagen type II synthesis, and chondrocyte ECM homeostasis. BPC-157 is a 15-amino-acid pentadecapeptide primarily investigated for angiogenic signaling, growth factor regulation, and soft tissue repair.
What are the recommended storage conditions for lyophilized Cartalax?
Lyophilized Cartalax should be stored at -20°C in a dry, dark environment for standard storage, or at -80°C for multi-year preservation. Protect vials from light, moisture, and elevated temperatures.
Does PX1 Research supply lot-specific Certificates of Analysis?
Yes. Every shipment of Cartalax includes or links to a lot-specific COA detailing HPLC purity chromatograms, mass spectrometry validation, and LAL endotoxin testing results from an ISO 17025 accredited laboratory.
What are the endotoxin limits for Cartalax supplied by PX1 Research?
PX1 Research enforces a strict bacterial endotoxin limit of <0.01 EU/mg for Cartalax, verified via Chromogenic LAL testing to ensure compatibility with sensitive cell cultures and biological assays.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.